The Department of Pathology and Cell Biology at Columbia University Medical Center

Invites you to join us

Celebrating 50 Years of the Rh Vaccine (RhoGAM)!

Monday, February 5, 2018

Vagelos Education Center, Room 902-903
104 Haven Avenue (at 171st Street)
New York, NY 10032

For more information and to RSVP, please contact Marquett Kennely, Executive Assistant, by email at: mk4067@cumc.columbia.edu or by phone at (212) 305 2204.

MORNING PROGRAM: 10:30-11:30 AM

Celebrating a Half Century of Success and Looking Ahead
Rh disease once claimed the lives of approximately 10,000 babies each year in the United States. In the 1960s, Dr. Vincent Freda, an obstetrician, and Dr. John Gorman, the Director of the Blood Bank, both at Columbia, conducted pioneering research that led to a breakthrough vaccine, effectively eradicating hemolytic disease of the newborn due to anti-Rh antibodies. Today, alongside patients and their families, we celebrate the 50th anniversary of that innovation with a special program that will address the success of this standard of care and the vision for making this therapy available to moms and babies around the world.

Featured speakers include:
Dr. Lee Goldman, Dean, Faculties of Health Sciences and Medicine
Chief Executive, Columbia University Medical Center *

Dr. Kevin Roth,
Donald W. King, M.D. and Mary Elizabeth King Professor of Pathology and Cell Biology
Chair Department of Pathology and Cell Biology

Dr. Mary D’Alton
Willard C. Rappleye Professor of Obstetrics and Gynecology
Chair, Department of Obstetrics and Gynecology

Paolo Marcucci, Chairman and CEO, Kedrion

AFTERNOON PROGRAM: 1:30 PM – 2:30 PM
Grand Rounds

Immunoprophylaxis Against Red Blood Cell Antigens: Successes and Failures

Featured speaker:
Jeanne Hendrickson, MD
Associate Professor of Laboratory Medicine and of Pediatrics; Associate Director, Transfusion Medicine Service, Yale University School of Medicine

Dr. Hendrickson is a pediatric hematologist and transfusion medicine specialist. Her clinical interests include factors influencing alloimmunization, particularly red blood cell alloimmunization, as well as strategies to minimize the formation and dangers of such antibodies. Her translational research interests include investigating the induction and consequences of red blood cell alloantibodies in transfusion and pregnancy situations, in murine models and in human clinical settings.